Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -90.60% | 93.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -90.60% | 93.07% | |||
| Cost of Revenue | -84.18% | 186.41% | |||
| Gross Profit | -92.98% | 72.20% | |||
| SG&A Expenses | 41.20% | -29.40% | |||
| Depreciation & Amortization | -15.73% | 11.25% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.03% | 4.75% | |||
| Operating Income | -236.59% | 440.63% | |||
| Income Before Tax | -296.12% | 277.18% | |||
| Income Tax Expenses | 0.00% | 75.00% | |||
| Earnings from Continuing Operations | -296.02% | 277.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -296.02% | 277.69% | |||
| EBIT | -236.59% | 440.63% | |||
| EBITDA | -230.56% | 482.96% | |||
| EPS Basic | -315.71% | 236.43% | |||
| Normalized Basic EPS | -315.13% | 165.03% | |||
| EPS Diluted | -20,700.00% | 101.43% | |||
| Normalized Diluted EPS | -25,700.00% | 100.55% | |||
| Average Basic Shares Outstanding | -8.70% | 22.05% | |||
| Average Diluted Shares Outstanding | -99.47% | 21,089.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||